US regulatory status: approved. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
pharma · Active Ulcerative Colitis
Tillotts Pharma AG
Tillotts Pharma AG drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
rheinfelden, DE HQ
293 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- rheinfelden, DE
- Employees
- 293
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Tillotts Pharma AG pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tillotts Pharma AG drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Tillotts Pharma AG in public FDA and regional records. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor